Buttock Implants in Alabama
Buttock Implants in Alabama section, includes general infrmation about Buttock Implants Procedure, Alabama Buttock Implants Local News, Alabama Buttock Implants Surgeon Locator and other Buttock Implants related material.
Alabama Buttock Implants - The Plastic Surgery Procedure
This surgical procedure also called gluteoplasty or buttock augmentation. It is designed to reshape the size of your buttocks and create more firm and aesthetic appearance. The buttock area is not easily changed by weight reduction or exercise, therefore you may consider this operation to improve the look of your buttock. In general, every person wishing to undergo the operation, and is in a good physical condition, can do so.
During the operation the surgeon inserts silicon implants into your gluteal area. Unlike breast implants, these are soft and solid, their shape and size vary, according to individual body form and desires.
Alabama Buttock Implants - The Implants
There are few kinds of implants: round or oval (also called an anatomic implant). The most common implants are those made of silicon. It comes with a smooth or textured surface and they are solid (meaning: they rarely spill or rupture). The selection of an implant is usually made according to the surgeon's advice and your preference.
Alabama Buttock Implants - Insertion Locations
The incision for the implant insertion can be made in several locations: two excisions, either on the superior buttocks or inferior buttock near the posterior thigh. Both incisions leave a quite visible scar. One excision is made in the sacrum area, it goes from top down, and is usually small (4-6cm). The only problem is that such incision tends to become infected more often; this can be treated with antibiotics. The implant can be placed above or below the gluteal muscles. Finally, a liposuction can be added to this procedure to further shape your buttocks.
This procedure is preformed under general anesthesia and usually lasts one hour, liposuction may require an additional half hour (consult local Alabama surgeon).
Alabama Buttock Implants - Risks
Every procedure has its risks: this one includes bleeding, infection, nerve and/or muscle damage and damage to the implants, such as silicon spillage and buttock asymmetry.
Alabama Buttock Implants - After Surgery
After surgery you will feel pain and discomfort, and you will be prescribed with painkillers. You also have to wear a special bandage for 2-3 weeks to help your buttocks gain their new look. Occasionally you may feel either temperature changes or numbness in the area. This will resolve after a few months. It may take about 3 months for the swelling to resolve and the buttocks to regain their final appearance. You'll be able to go back to full activity after one month. Since the implants are placed far from the bony area you will have no trouble sitting. Finally, the implants will give your butt the look like you have been working out for years.
Other Alabama Body Procedures
All Body Procedures
Alabama Buttock Implants (current)
Alabama Buttock Augmentation
Alabama Liposuction
Alabama Vaginal Surgery
Alabama Body Cotouring
More Alabama info...
Alabama Festivals
Gulf Shores is home to the National Shrimp Festival. This outdoor event is held annually in October and features over 300 vendors that offer fine art, arts and crafts, an international marketplace and plenty of shrimp. Three stages also carry music continuously throughout the festival. Over 200,000 people attend the festival annually and it has been ranked as one of the top twenty events in the southeast by the Southeast Tourism Society, and one of the top five in the state. 2006 will mark the 35th anniversary of this festival.
Alabama Golf
Robert Trent Jones Golf Trail, 100 Sunbelt Parkway, ? +1 205-942-1177 or 1-800-949-4444 (info@rtjgolf.com, fax: +1 205-290-1230), [4]. Ten public golf courses throughout Alabama. $40-125 per course.
Plastic Surgery News...
- The House Energy and Commerce Subcommittee on Health on Tuesday held a hearing to review efforts in 2007 to pass legislation to reauthorize and expand SCHIP, CQ Today reports.
- The FDA has issued new information to health care professionals about an increased risk of suicidal thoughts and behaviours (suicidality) in patients taking antiepileptics to treat epilepsy, bipolar disorder, migraine headaches, and other conditions.
This information was issued following an analysis of suicidality reports from 199 placebo-controlled studies of 11 antiepileptic drugs: 27,863 patients in drug treatment groups and 16,029 patients in placebo groups. There were four suicides among patients in the drug treatment groups and none among patients in placebo groups. There were 105 reports of suicidal thoughts or behaviours in the drug-treated patients and 35 reports in placebo-treated patients. These data therefore indicated that patients on these drugs had twice the risk of suicidal thoughts and behaviours (0.43%) vs. patients on placebo (0.22%), corresponding to an estimated 2.1 more events per 1000 patients in the drug treatment groups who experienced suicidality vs. placebo groups (estimated NNH ~ 500). The higher risk of suicidal thoughts and behaviours was observed at one week after starting a drug and continued to at least 24 weeks. The results were generally consistent among all the different drug products studied and were seen in all demographic subgroups. There was no clear pattern of risk across age groups.
Antiepileptic drugs in the analyses included the following: carbamazepine, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, valproate and zonisamide. However the FDA expects that all medications in the antiepileptic class share the increased risk of suicidality. The agency will be working with the drug manufacturers to include this new information in the labelling for these products. In the meantime, the agency stresses that patients who are currently taking antiepileptics should not make any changes without first talking to their clinician and health care professionals are advised to notify patients on such treatments of this risk.